Synthesis and structure-activity relationships of aminoalkylazetidines as ORL1 receptor ligands

Bioorganic and Medicinal Chemistry Letters

Volumn 12, Issue 21, 2002, Pages 3157-3160

  Wu, Wen Lian ^a   Caplen, Mary Ann ^a   Domalski, Martin S ^a   Zhang, Hongtao ^a   Fawzi, Ahmad ^a   Burnett, Duane A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZETIDINE; AZETIDINE DERIVATIVE; ORL1 RECEPTOR; RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING ASSAY; BINDING COMPETITION; CONTROLLED STUDY; DIASTEREOISOMER; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; RECEPTOR AFFINITY; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANIMALS; AZETIDINES; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; DIPRENORPHINE; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; INDICATORS AND REAGENTS; LIGANDS; NARCOTIC ANTAGONISTS; OPIOID PEPTIDES; RECEPTORS, OPIOID; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037020755     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(02)00652-2     Document Type: Article

References (22)

1. (a) Mollereau C., Parmentier M., Mailleux P., Butour J.L., Moisand C., Chalon P., Caput D., Vassart G., Meunier J.C. FEBS Lett. 341:1994;33.
2. (b) Keith D. Jr., Maung T., Auton B., Evans C. Regul. Pept. 54:1994;143.
3. (c) Wick M.J., Minnerath S.R., Lin X., Elde R., Law P.Y., Loh H.H. Mol. Brain Res. 27:1994;37.
4. (d) Wang J.B., Johnson P.S., Imai Y., Persico A.M., Ozenberger B.A., Eppler C.M., Uhl G.R. FEBS Lett. 348:1994;75.
5. (a) Reinscheid R.K., Nothacker H.P., Bourson A., Ardati A., Henningsen R.A., Bunzow J.R., Grandy D.K., Langen H., Monsma F.J., Civelli O. Jr. Science. 270:1995;792.
6. (b) Meunier J.-C., Mollereau C., Toll L., Suaudeau C., Moisand C., Alvinerie P., Butour J.L., Guillemot J.C., Ferrara P., Monsarrat B., Mazarguil H., Vassart G., Parmentier M., Costentin J. Nature (London). 377:1995;532.
7. Meunier J.-C. Exp. Opin. Ther. Patents. 10:2000;371. and references cited therein.
8. (a) Hiroshi K., Ozaki S., Itoh Y., Miyaji M., Arai S., Nakashima H., Kato T., Ohta H., Iwasawa Y. J. Med. Chem. 42:1999;5061.
9. (b) Röver S., Wichmann J., Jenck F., Adam G., Cesura A.M. Bioorg. Med. Chem. Lett. 10:2000;831.
10. (c) Röver S., Adam G., Cesura A.M., Galley G., Jenck F., Monsma F.J. Jr., Wichmann J., Dautzenberg F.M. J. Med. Chem. 43:2000;1329
11. (d) Shinkai H., Ito T., Iida T., Kitao Y., Yamada H., Uchida I. J. Med. Chem. 43:2000;4667
12. (e) Kawamoto H., Ozaki S., Itoh Y., Miyaji M., Arai S., Nakashima H., Kato T., Ohta H., Iwasawa Y. J. Med. Chem. 42:1999;5061
13. (f) For an excellent review, see Ronzoni S., Peretto I., Giardian G.A.M. Exp. Opin. Ther. Patents. 11:2001;525., and references cited therein.
14. We thank Professor Andrew McPhail of Duke University for the determination of the X-ray structure.
15. This approach is predicated on a related route to erythro aminoalkylazetidines. D. Solomon, SPRI, unpublished results.
16. Viaud M.C., Rollin P. Synthesis. 1990;130.
17. Sarma J.C., Sharma R.P. Chemistry and Industry. 764:1987.
18. +, 100%).
19. (a) Fawzi A.B., Zhang H., Weig B., Hawes B., Graziano M.P. Eur. J. Pharmacol. 336:1997;233
20. (b) Corboz M.R., Rivelli M.A., Egan R.W., Tulshian D., Matasi J., Fawzi A.B., Benbow L., Smith-Torhan A., Zhang H., Hey J.A. Eur. J. Pharmacol. 402:2000;171.
21. Kocienski P.J., Yeates C., Street S.D.A., Campbell S.F. J. Chem. Soc., Perkin Trans. 1. 1987;2183.
22. Lemaire-Audoire S., Savignac M., Genêt J.P. Tetrahedron Lett. 36:1995;1267.